{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T15:54:13Z","timestamp":1764777253756,"version":"3.46.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Syst. Biol."],"abstract":"<jats:p>Cystic fibrosis (CF) is the most prevalent inherited disease. Inactivating mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene lead to the accumulation of viscous mucus and subsequent respiratory complications. This study optimized a prime editing (PE) approach to correct CFTR mutations focusing on the F508del mutation. Prime editing allowed to introduce missing bases without double-strand breaks using a Cas9-nickase fused with a reverse transcriptase in combination with a prime editing guide RNA (pegRNA). Various self-designed pegRNAs were compared. For delivery, various lipid nanoparticles (LNP) were tested, which were optimized for stability and lung cells targeting based on lipid selection or chitosan complexion. A fluorescence reporter system, pPEAR_CFTR, was developed mimicking F508del for validation. The five pegRNAs yielding the highest efficiency were used for genomic CFTR correction in a CF bronchial cell line. Nanopore sequencing of genomic DNA revealed approximate 5% edited reads. These results highlight the promise of prime editing-LNP systems for precise and lung-specific gene correction, paving the way for novel therapies in cystic fibrosis and other pulmonary genetic disorders.<\/jats:p>","DOI":"10.3389\/fsysb.2025.1603749","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T15:50:23Z","timestamp":1764777023000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Towards effective cystic fibrosis gene therapy by optimizing prime editing and pulmonary-targeted LNPs"],"prefix":"10.3389","volume":"5","author":[{"given":"Kaya Sophie","family":"Lange","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa Marie","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Susat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte","family":"Lenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Alexander","family":"Michalek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Lena","family":"Baack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip Frederic","family":"Mundt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Kanthak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabell Alexandra","family":"Guckes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Haverkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Utkarsh Anil","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicitas Helena","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinan","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Tobias","family":"Radukic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levin Joe","family":"Klages","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rn","family":"Kalinowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian Mark","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.3390\/ijms20215463","article-title":"Unravelling the regions of mutant F508del-CFTR more susceptible to the action of four cystic fibrosis correctors","volume":"20","author":"Amico","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jconrel.2024.11.010","article-title":"Exploring the impact of commonly used ionizable and pegylated lipids on mRNA-LNPs: A combined in vitro and preclinical perspective","volume":"377","author":"Binici","year":"2025","journal-title":"J. Contr. Release"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1007\/s00431-021-04168-y","article-title":"A new era for people with cystic fibrosis","volume":"180","author":"Bierlaagh","year":"2021","journal-title":"Eur. J. Pediatr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"101544","DOI":"10.1016\/j.xcrm.2024.101544","article-title":"Prime editing functionally corrects cystic fibrosis-causing CFTR mutations in human organoids and airway epithelial cells","volume":"5","author":"Bulcaen","year":"2024","journal-title":"Cell Rep. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","article-title":"Enhanced prime editing systems by manipulating cellular determinants of editing outcomes","volume":"184","author":"Chen","year":"2021","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ymthe.2021.01.010","article-title":"Gene therapy for cystic fibrosis: lessons learned and paths forward","volume":"29","author":"Choi","year":"2021","journal-title":"Mol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1021\/acs.molpharmaceut.4c01039","article-title":"Lipid nanoparticles and PEG: time frame of immune checkpoint blockade can be controlled by adjusting the rate of cellular uptake of nanoparticles","volume":"22","author":"Choi","year":"2025","journal-title":"Mol. Pharm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41551-020-00622-8","article-title":"A web tool for the design of prime-editing guide RNAs","volume":"5","author":"Chow","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"B11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: a disease with a new face","volume":"109","author":"De Boeck","year":"2020","journal-title":"Acta Paediatr."},{"key":"B12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1016\/j.cell.2023.07.039","article-title":"Phage-assisted evolution and protein engineering yield compact, efficient prime editors","volume":"186","author":"Doman","year":"2023","journal-title":"Cell"},{"key":"B13","volume-title":"Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products","year":"2018"},{"key":"B3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41587-025-02616-w","volume":"43","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/ph15020217","article-title":"N-acetylcysteine (NAC) and its role in clinical practice management of cystic fibrosis (CF): a review","volume":"15","author":"Guerini","year":"2022","journal-title":"Pharmaceuticals"},{"key":"B14","doi-asserted-by":"publisher","first-page":"8552","DOI":"10.3748\/wjg.v19.i46.8552","article-title":"Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases","volume":"19","author":"Haack","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"eadd4623","DOI":"10.1126\/sciadv.add4623","article-title":"Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates","volume":"9","author":"Herrera-Barrera","year":"2023","journal-title":"Sci. Adv."},{"key":"B15","doi-asserted-by":"publisher","first-page":"a009498","DOI":"10.1101\/cshperspect.a009498","article-title":"The CFTR ion channel: gating, regulation, and anion permeation","volume":"3","author":"Hwang","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2301241","DOI":"10.1183\/13993003.01241-2023","article-title":"Cystic fibrosis in Europe: improved lung function and longevity \u2013 reasons for cautious optimism, but challenges remain","volume":"63","author":"Kerem","year":"2024","journal-title":"Eur. Respir. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/1945892420912368","article-title":"Cystic fibrosis transmembrane conductance regulator modulator therapy: a review for the otolaryngologist","volume":"34","author":"Lee","year":"2020","journal-title":"Am. J. Rhinol. Allergy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1093\/bioinformatics\/bty191","article-title":"Minimap2: pairwise alignment for nucleotide sequences","volume":"34","author":"Li","year":"2018","journal-title":"Bioinformatics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41467-022-29339-9","article-title":"Highly efficient prime editing by introducing same-sense mutations in pegRNA or stabilizing its structure","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2017.02.024","article-title":"Molecular structure of the human CFTR ion channel","volume":"169","author":"Liu","year":"2017","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.32607\/actanaturae.11708","article-title":"Gene therapy for cystic fibrosis: recent advances and future prospects","volume":"15","author":"Lomunova","year":"2023","journal-title":"Acta Naturae"},{"key":"B22","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.ymthe.2005.02.010","article-title":"A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer\/therapy","volume":"11","author":"Moghimi","year":"2005","journal-title":"Mol. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41587-021-01039-7","article-title":"Engineered pegRNAs improve prime editing efficiency","volume":"40","author":"Nelson","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","article-title":"Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA","volume":"11","author":"Patel","year":"2020","journal-title":"Nat. Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1100\/2012\/465230","article-title":"Hypertonic saline in treatment of pulmonary disease in cystic fibrosis","volume":"2012","author":"Reeves","year":"2012","journal-title":"Sci. World J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"12771","DOI":"10.1073\/pnas.0906850106","article-title":"Basal cells as stem cells of the mouse trachea and human airway epithelium","volume":"106","author":"Rock","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B24","doi-asserted-by":"publisher","first-page":"s475","DOI":"10.1590\/S0102-311X2008001600002","article-title":"Cystic fibrosis and neonatal screening","volume":"24","author":"Rodrigues","year":"2008","journal-title":"Cad. Sa\u00fade P\u00fablica"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e69504","DOI":"10.7554\/eLife.69504","article-title":"PEAR, a flexible fluorescent reporter for the identification and enrichment of successfully prime edited cells","volume":"11","author":"Simon","year":"2022","journal-title":"eLife"},{"key":"B26","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jconrel.2024.04.022","article-title":"Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies \u2013 challenges and opportunities","volume":"370","author":"Simonsen","year":"2024","journal-title":"J. Control. Release"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41551-024-01233-3","article-title":"Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cells","author":"Sousa","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"B27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","article-title":"Delivery of CRISPR-cas tools for in vivo genome editing therapy: trends and challenges","volume":"342","author":"Taha","year":"2022","journal-title":"J. Control. Release"},{"key":"B28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/bib\/bbs017","article-title":"Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration","volume":"14","author":"Thorvaldsdottir","year":"2013","journal-title":"Brief. Bioinform."},{"key":"B29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/d41573-023-00002-2","article-title":"The landscape for lipid-nanoparticle-based genomic medicines","volume":"22","author":"Verma","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"B30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"105547","DOI":"10.1016\/j.jddst.2024.105547","article-title":"The optimization strategies of LNP-mRNA formulations: development and challenges for further application","volume":"95","author":"Wang","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.2147\/IJN.S359118","article-title":"The mucoadhesive nanoparticle-based delivery system in the development of mucosal vaccines","volume":"17","author":"Zhao","year":"2022","journal-title":"Int. J. Nanomedicine"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.1021\/jp809000e","article-title":"The role of cholesterol and structurally related molecules in enhancing transfection of cationic Liposome\u2212DNA complexes","volume":"113","author":"Zidovska","year":"2009","journal-title":"J. Phys. Chem. B"},{"key":"B34","volume-title":"ECFSPR annual report 2022","author":"Zolin","year":"2024"}],"container-title":["Frontiers in Systems Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsysb.2025.1603749\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T15:50:25Z","timestamp":1764777025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsysb.2025.1603749\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":42,"alternative-id":["10.3389\/fsysb.2025.1603749"],"URL":"https:\/\/doi.org\/10.3389\/fsysb.2025.1603749","relation":{},"ISSN":["2674-0702"],"issn-type":[{"value":"2674-0702","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"article-number":"1603749"}}